Botanix Pharmaceuticals Limited (ASX:BOT)

Market Cap	124.12M -83.8%
Revenue (ttm)	5.79M +179.7%
Net Income	-86.40M
EPS	-0.05
Shares Out	1.97B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,986,802
Average Volume	11,652,519
Open	0.0630
Previous Close	0.0630
Day's Range	0.0600 - 0.0640
52-Week Range	0.0600 - 0.5350
Beta	1.03
RSI	22.71
Earnings Date	Feb 27, 2026

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 11
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BOT

Financial Performance

In fiscal year 2025, Botanix Pharmaceuticals's revenue was 5.79 million, an increase of 179.74% compared to the previous year's 2.07 million. Losses were -86.40 million, 522.9% more than in 2024.